NDatalyze Announces YMI mHealth App Beta Now Live

0

(via TheNewswire)

Calgary, ABTheNewswire –March 8, 2022For Immediate Release –nDatalyze Corp.(“NDAT” Whereyouhe “society”)(CSE:NDAT),(OTC: NDATF)is pleased to announce that the beta version of the YMI mHealth app is now live on the Company’s website athttps://www.ymihealth.com/ (copy/paste if the link does not work). During the beta testing period, access is limited and individuals interested in becoming beta testers should contact the Company to inquire about eligibility.

James DurwardPresident, says, “With mental health now ‘front and center’ in today’s society, we believe YMI is the right product at the right time. Today’s beta incorporates predicted probabilities in time on anxiety, depression, PTSD and OCD, four of today’s most common mental conditions.This advanced product was made possible by our proprietary benchmark database and algorithms. The YMI interface now features many additions based on feedback from our recent third-party marketing research and the beta is designed to allow further refinement of demographics, look&feel and pricing. of YMI is made available free of charge to a limited number of demographically defined participants and we plan to open YMI to the general public in the near future.”

The Company further reports that it plans to integrate the final three conditions of bipolar, alcoholism, and personality disorders during or shortly after the end of the beta.

On nDatalyze Corp.:

nDatalyze Corp. generates technological solutions related to health. The YMI division is developing a consumer mental health application based on machine learning and the MLdelic division is focusing on the application of machine learning to aid in the prediction of potential benefits associated with the use of entheogenic compounds in the mental health sector. Both YMI and MLdelic are based on the company’s proprietary reference database of over 1200 complete biometric records with EEG data “at the same time of day”. With installations around the world, its Medxtractor manufactures and sells small-scale bio-extractors that are used to extract compounds from a variety of botanical biomasses. While the Medxtractor division currently generates cash flow, both YMI and MLdelic are in development and therefore the Company cannot accurately predict if or when these applications will become cash flow generating.

FOR MORE INFORMATION, PLEASE CONTACT:

nDatalyze Corp.

James DurwardPresident and CEO

Phone: (403) 689-3901

E-mail:[email protected] Website:www.ndatalyze.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities of United States. The Securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “we Securities Act”) or any state securities law and may not be offered or sold in United States or for we Persons, unless registered under the we Securities Act and applicable state securities laws or an exemption from such registration is available.

The information in this press release includes certain information and statements about management’s views on future events, expectations, plans and prospects that constitute forward-looking statements. These statements are based on assumptions subject to significant risks and uncertainties. Due to these risks and uncertainties and due to various factors, actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. A number of factors could cause actual results to differ materially from these forward-looking statements and from future results. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the expectations in the forward-looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and undertakes no obligation to update or revise forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting these forward-looking statements or otherwise.

Copyright (c) 2022 TheNewswire – All Rights Reserved.

Copyright (c) 2022 TheNewswire – All rights reserved., source Press Releases

Share.

Comments are closed.